Uplizna 100 mg concentrate for solution for infusion

DRUG3 trials

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Amgen Inc.

Conditions

Generalized Myasthenia GravisImmunoglobulin G4 related Disease (IgG4-RD)anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis)

Phase 2

A PHASE-2B, DOUBLE-BLIND, RANDOMIZED CONTROLLED TRIAL TO EVALUATE THE ACTIVITY AND SAFETY OF INEBILIZUMAB IN ANTI-NMDA RECEPTOR ENCEPHALITIS AND ASSESS MARKERS OF DISEASE (EXTINGUISH)

RecruitingCTIS2023-504686-23-00

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)anti-N-methyl-D-aspartate receptor encephalitis (anti-NMDAR encephalitis)

Start: 2024-12-10Target: 26Updated: 2025-11-13

A Phase 2 Open-label Multicenter study to evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in children from 2 years to less than 18 years of age with generalized Myasthenia Gravis (gMG)

Not yet recruitingCTIS2025-520993-20-00

Amgen Inc.Generalized Myasthenia Gravis

Target: 4Updated: 2026-02-11

Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)

Not yet recruitingCTIS2025-520988-41-00

Amgen Inc.Immunoglobulin G4 related Disease (IgG4-RD)

Target: 2Updated: 2026-02-25